Can serum level of NT-PRO BNP be used in Psoriatic patients as a predictor of cardiovascular disease

Background: Past studies have reported associations between psoriasis, metabolic syndrome and atherosclerotic cardiovascular disease.According to studies, NTproBNP is a useful screening test for cardiac disease. Objectives: We examined the serum NT-proBNP level in patients with psoriasis and compared them with nonpsoriatic healthy control subjects. Material and Methods: Sixty-one patients with chronic plaque-type psoriasis were enrolled, along with 61 age and sex matched control subjects. In both groups, NT-pro BNP serum levels and lipid profile parameters were investigated. Results: The serum concentration of NT-proBNP was significantly higher in psoriaticpatients (38.057±39.53pg/ml) (p<0.001) than the control group (17.46±7.24pg/ml). NT-proBNP serum level in psoriatic arthritis patients (11%) was higher than psoriasis patients without arthritis (p<0.01).In addition, the positive correlations between the NT-proBNP with BMI, lipid profile and disease duration were observed. Conclusions: Patients with psoriasis are at high risk for cardiovascular disease. NTproBNP is an easily utilizable biomarker for risk assessment of cardiovasculardisease.

Keywords:

Psoriasis , NT-pro BNP , Cardiovascular